Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Akero Therapeutics ( (AKRO) ) has issued an announcement.
On January 27, 2025, Akero Therapeutics reported promising preliminary results from their Phase 2b SYMMETRY study, which evaluated the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to MASH. The study showed significant improvements in fibrosis without worsening MASH, with 39% of patients in the 50mg EFX group showing positive results compared to 15% in the placebo group. These findings underscore the potential of EFX as a transformative treatment, marking a notable advancement in addressing cirrhosis caused by MASH and enhancing Akero’s position in the metabolic disease treatment landscape. The treatment was generally well-tolerated, and no serious adverse events related to EFX were reported.
More about Akero Therapeutics
Akero Therapeutics is a clinical-stage company focusing on developing transformational treatments for serious metabolic diseases, particularly targeting metabolic dysfunction-associated steatohepatitis (MASH). Their lead product, efruxifermin (EFX), aims to address the high unmet medical need in this area.
YTD Price Performance: -6.77%
Average Trading Volume: 724,162
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.83B
See more insights into AKRO stock on TipRanks’ Stock Analysis page.
